Submission of financial result approved by board of director on 07.06.2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Choksi Laboratories posted FY25 revenue from operations of ₹4,184.94 lakhs, up 13.55% from ₹3,685.92 lakhs in FY24. Net profit for the year rose 37.3% to ₹152.33 lakhs (from ₹110.98 lakhs), with basic EPS of ₹2.19 versus ₹1.59. Q4 FY25 revenue grew modestly to ₹1,144.38 lakhs, while Q4 net profit jumped nearly 35% to ₹92.13 lakhs. Finance costs came down about 12% YoY, supporting the profit growth. The statutory auditor (Prateek Jain & Co.) issued an unqualified opinion but highlighted a May 22, 2025 ransomware attack that temporarily disrupted operations and caused the board meeting to be deferred from May 29 to June 7. Total borrowings stand at roughly ₹2,807 lakhs against equity of ₹2,360 lakhs, keeping the company in a leveraged position.
Healthy profit growth and easing finance costs are positives for shareholders, but the recent ransomware breach and elevated debt levels (D/E around 1.2x) warrant close watch for any further costs or operational fallout in the coming quarters.